Elevance Health Beats Q2 Estimates on CarelonRx Revenue Growth
Elevance Health beat Q2 earnings and revenue estimates, driven by higher CarelonRx product revenues. The company raised its 2026 adjusted EPS guidance despite lower earnings and softer membership.
Key Numbers
Elevance Health (ELV) reported second-quarter 2026 results that surpassed analyst estimates for both revenue and earnings, fueled by strong growth in CarelonRx product revenues. The stock edged higher in early trading.
Key Financial Results
| Metric | Q2 2026 | YoY Change |
|---|---|---|
| Revenue | $43.2B | +8% |
| Net Income | $3.1B | -2% |
| EPS | $9.87 | +5% |
Highlights from the Release
The company attributed its strong performance to higher revenues from CarelonRx, its pharmacy benefit management segment. However, net income declined due to increased expenses and a slight drop in membership.
Forward Guidance
Elevance Health raised its 2026 adjusted EPS guidance to $37.50, up from the prior outlook of $36.80.
Stock Impact
ELV shares rose 1.2% in pre-market trading, reflecting investor optimism over the beat and raised guidance.
What This Means for Investors
Despite challenges from rising costs and softer membership, CarelonRx's revenue growth bolsters confidence in the company's ability to meet its annual targets.
Frequently Asked Questions
Found this useful? Share it